Department of Infectious Diseases, the First Affiliated Hospital of Zhengzhou University, Νo. 1 Jianshe East Road, Zhengzhou, 450000, Henan, People's Republic of China.
Mol Cell Biochem. 2019 Jan;450(1-2):125-134. doi: 10.1007/s11010-018-3379-8. Epub 2018 Jun 15.
Hepatocellular carcinoma (HCC) is one of the most common types of malignant tumors with high recurrence and metastasis rates. Radiotherapy represents a major therapeutic option for HCC patients. However, the efficacy of radiotherapy has been limited due to the development of intrinsic radioresistance of the tumor cells. Small ubiquitin-like modifier 1 pseudogene 3 (SUMO1P3), one member of SUMO pseudogene family, is a novel identified lncRNA that was originally identified to be upregulated in gastric cancer. However, the detailed roles of SUMO1P3 in HCC development remain to be elucidated. Here, the expression of SUMO1P3 in HCC tissues and cells was examined by qRT-PCR. Cell proliferation, colony formation ability, invasion ability, apoptosis, and radiosensitivity were detected by MTT assay, colony formation assay, cell invasion assay, flow cytometry analysis, and survival fraction assay, respectively. We found that SUMO1P3 was significantly upregulated in HCC tissues and cells. Besides, SUMO1P3 was highly expressed in HCC patients with higher TNM stage. Furthermore, SUMO1P3 knockdown markedly suppressed cell proliferation, colony formation ability, and cell invasiveness, promoted apoptosis, and enhanced radiosensitivity of HCC cells. We concluded that the knockdown of SUMO1P3 repressed tumor growth, invasion, promoted apoptosis, and enhanced radiosensitivity in HCC, providing evidence that SUMO1P3 might be a potential novel biomarker and a therapeutic target for HCC.
肝细胞癌（HCC）是最常见的恶性肿瘤类型之一，具有高复发和转移率。放射治疗是 HCC 患者的主要治疗选择之一。然而，由于肿瘤细胞内在的放射抵抗性的发展，放射治疗的疗效受到限制。小泛素样修饰物 1 假基因 3（SUMO1P3）是 SUMO 假基因家族的一个成员，是一种新鉴定的 lncRNA，最初在胃癌中被鉴定为上调。然而，SUMO1P3 在 HCC 发展中的详细作用仍有待阐明。在这里，通过 qRT-PCR 检测 HCC 组织和细胞中 SUMO1P3 的表达。通过 MTT 测定、集落形成测定、细胞侵袭测定、流式细胞术分析和存活分数测定分别检测细胞增殖、集落形成能力、侵袭能力、凋亡和放射敏感性。我们发现 SUMO1P3 在 HCC 组织和细胞中显著上调。此外，SUMO1P3 在 TNM 分期较高的 HCC 患者中高表达。此外，SUMO1P3 敲低显著抑制 HCC 细胞的增殖、集落形成能力和细胞侵袭性，促进细胞凋亡，并增强 HCC 细胞的放射敏感性。我们得出结论，SUMO1P3 的敲低抑制了肿瘤生长、侵袭，促进了 HCC 中的细胞凋亡，并增强了放射敏感性，为 SUMO1P3 可能是 HCC 的潜在新型生物标志物和治疗靶点提供了证据。
